Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals has raised $201.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Corvus Pharmaceuticals's investors include BlackRock, Cormorant Asset Management, Adams Street Partners, Point72, OrbiMed.
Corvus Pharmaceuticals is headquartered in Burlingame, United States.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Corvus Pharmaceuticals — Funding & Investors." VCBacked, January 21, 2026, https://www.vcbacked.co/company/corvus-pharmaceuticals. Accessed August 11, 2026.
VCBacked. (2026). Corvus Pharmaceuticals — Funding & Investors. Retrieved August 11, 2026, from https://www.vcbacked.co/company/corvus-pharmaceuticals
{{cite web |title=Corvus Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/corvus-pharmaceuticals |website=VCBacked |access-date=August 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated